Original research article| Volume 89, ISSUE 3, P193-196, March 2014

Reduction in infection-related mortality since modifications in the regimen of medical abortion



      From 2001 to March 2006 Planned Parenthood health centers throughout the United States provided medical abortion by a regimen of oral mifepristone followed 24–48 h later by vaginal misoprostol. In response to concerns about serious infections, in early 2006 Planned Parenthood changed the route of misoprostol administration to buccal and required either routine antibiotic coverage or universal screening and treatment for chlamydia; in July 2007, Planned Parenthood began requiring routine antibiotic coverage for all medical abortions.


      We performed a retrospective analysis of Planned Parenthood cases assessing the rates of mortality caused by infection following medical abortion during a time period when misoprostol was administered vaginally (2001 through March 2006), as compared with the rate from April 2006 to the end of 2012 after a change to buccal administration of misoprostol and after initiation of new infection-reduction strategies.


      The mortality rate dropped significantly in the 81-month period after the joint change to (1) buccal misoprostol replacing vaginal misoprostol and (2) either sexually transmitted infection (STI) screening or routine preventative antibiotic coverage (15 month period) or universal routine preventative antibiotic coverage as part of the medical abortion (66-month period), from 1.37/100,000 to 0.00/100,000, P=.013 (difference=1.37/100,000, 95% CI 0.47–4.03 per 100,000).


      The infection-caused mortality rate following medical abortion declined by 100% following a change from vaginal to buccal administration of misoprostol combined with screen-and-treat or, far more commonly, routine antibiotic coverage.


      Deaths from infection following medical abortion declined to zero after a change in the regimen.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Contraception
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Sawaya G.F.
        • Grady D.
        • Kerlikowske K.
        • Grimes D.A.
        Antibiotics at the time of induced abortion: the case for universal prophylaxis based on a meta-analysis.
        Obstet Gynecol. 1996; 87: 884-890
        • Spitz I.M.
        • Bardin C.W.
        • Benton L.
        • Robbins A.
        Early pregnancy termination with mifepristone and misoprostol in the United States.
        N Engl J Med. 1998; 338: 1241-1247
        • Hausknecht R.
        Mifepristone and misoprostol for early medical abortion: 18 months experience in the United States.
        Contraception. 2003; 67: 463-465
        • Shannon C.
        • Brothers L.P.
        • Philip N.M.
        • Winikoff B.
        Infection after medical abortion: a review of the literature.
        Contraception. 2004; 70: 183-190
        • Henderson J.T.
        • Hwang A.C.
        • Harper C.C.
        • Stewart F.H.
        Safety of mifepristone abortions in clinical use.
        Contraception. 2005; 72: 175-178
        • Fischer M.
        • Bhatnagar J.
        • Guarner J.
        • et al.
        Fatal toxic shock syndrome associated with Clostridium sordellii after medical abortion.
        N Engl J Med. 2005; 353: 2352-2360
        • Darney P.D.
        Letter to the editor on deaths associated with medication abortion.
        Contraception. 2005; 72: 319
      1. Accessed November 15, 2013.


        • Centers for Disease Control, Prevention
        Sexually Transmitted Disease Surveillance 2006 Supplement, Gonococcal Isolate Surveillance Project (GISP) Annual Report 2006.
        U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, Atlanta, GA2008
        • Winikoff B.
        • Dzuba I.G.
        • Creinin M.D.
        • Crowden W.A.
        • Goldberg A.B.
        • Gonzales J.
        • et al.
        Two distinct oral routes of misoprostol in mifepristone medical abortion: a randomized controlled trial.
        Obstet Gynecol. 2008; 112: 1303-1310
        • Fjerstad M.
        • Trussell J.
        • Sivin I.
        • Lichtenberg E.S.
        • Cullins V.
        Rates of serious infection after changes in regimens for medical abortion.
        N Engl J Med. 2009; 361: 145-151
        • Berg C.J.
        • Callaghan W.M.
        • Syverson C.
        • Henderson Z.
        Pregnancy-related mortality in the United States, 1998 to 2005.
        Obstet Gynecol. 2010; 116: 1302-1309
        • Fjerstad M.
        • Sivin I.
        • Lichtenberg E.S.
        • Trussell J.
        • Cleland K.
        • Cullins V.
        Effectiveness of medical abortion with mifepristone and buccal misoprostol through 59 gestational days.
        Contraception. 2009; 80: 282-286
        • Cleland K.
        • Creinin M.D.
        • Nucatola D.
        • Nshom M.
        • Trussell J.
        Significant adverse events and outcomes after medical abortion.
        Obstet Gynecol. 2013; 121: 166-171